Prescribing Antidiabetic Medications Among GPs in Croatia—A Real-Life Cross-Sectional Study

QR Code

Prescribing Antidiabetic Medications Among GPs in Croatia—A Real-Life Cross-Sectional Study

<b>Background</b>: Advances in the treatment of type 2 diabetes (T2D) in recent decades have been primarily focused on its broader understanding in the context of the possibility of preventing the development and progression of the disease and of cardiovascular (CV) complications. Nevert...

Full description

Saved in:

Bibliographic Details
Main Authors:	Tomislav Kurevija, Ema Schönberger, Matea Matić Ličanin, Ines Bilić-Ćurčić, Ljiljana Trtica-Majnarić, Silvija Canecki-Varžić
Format:	Article
Language:	English
Published:	MDPI AG 2025-06-01
Series:	Biomedicines
Subjects:	type 2 diabetes cardiovascular risk SGLT2ins GLP-1 RAs family medicine
Online Access:	https://www.mdpi.com/2227-9059/13/6/1491
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

¿Combinamos AR-GLP1 + i-SGLT2? Sí o no
by: Claudia Folino
Published: (2024-10-01)

Suboptimal physician adherence to evidence‐based guidelines for managing cardiorenal comorbidities in diabetes care: A retrospective single‐center study in Taiwan
by: Zong‐Yu Shen, et al.
Published: (2025-08-01)

Genetic variability in sodium-glucose cotransporter 2 and glucagon-like peptide 1 receptor effect on glycemic and pressure control in type 2 diabetes patients treated with SGLT2 inhibitors and GLP-1RA in the everyday clinical practice
by: Gašper Tonin, et al.
Published: (2025-07-01)

Innovations in Pharmacotherapy of Diabetes: A Review of Latest Reports
by: Katarzyna Czechowska, et al.
Published: (2025-07-01)

The Effect of Frailty on Body Composition and Its Impact on the Use of SGLT-2 Inhibitors and GLP-1RA in Older Persons with Diabetes
by: Alan Sinclair, et al.
Published: (2025-06-01)

A decade of progress in type 2 diabetes and cardiovascular disease: advances in SGLT2 inhibitors and GLP-1 receptor agonists – a comprehensive review
by: David Aristizábal-Colorado, et al.
Published: (2025-07-01)

The relationship between antidiabetic and renal cancer: a systematic review
by: Shadman Newaz, et al.
Published: (2025-06-01)

Is the Impact of Sodium–Glucose Co-Transporter 2 (SGLT2) Inhibitors on Bone Metabolism and Fracture Incidence a Class or Drug Effect? A Narrative Review
by: George I. Lambrou, et al.
Published: (2025-04-01)

Canagliflozin and risk of amputation in patients with type 2 diabetes
by: T. M. Bukatina, et al.
Published: (2018-02-01)

Inhibitors of sodium-glucose cotransporter 2: risk of ketoacidosis
by: T. M. Bukatina, et al.
Published: (2018-02-01)

Ketoacidosis as unexpected adverse reaction SGLT<sub>2</sub> inhibitor
by: T. M. Bukatina, et al.
Published: (2018-02-01)

Investigating the effect of SGLT2 inhibitors on cardiovascular related health status in HFmrEF and HFpEF: systematic review and meta analysis
by: Tabitha Kusi-Yeboah, et al.
Published: (2025-07-01)

The Efficacy and Safety of Sodium Glucose Cotransporter 2 Inhibitors for Patients with Anticancer Therapy: A Meta-Analysis of Cohort Studies
by: Gang Fan, et al.
Published: (2025-06-01)

SGLT2 inhibitors: control of glycemia and nephroprotection properties
by: A. A. Volodin, et al.
Published: (2018-02-01)

Early Recognition of Type 2 Diabetes Complications and Use of SGLT2i in Multidisciplinary Approach: Indonesian Perspective - An Expert Opinion
by: Aida Lydia, et al.
Published: (2023-01-01)

EVALUAREA EFICACITĂȚII TERAPIEI CU INHIBITORI SGLT2 LA PACIENȚII CU INSUFICIENȚĂ CARDIACĂ CU FRACȚIE DE EJECȚIE PĂSTRATĂ
by: Tatiana Cotonet, et al.
Published: (2025-03-01)

Evaluating Guideline Alignment by Analyzing Patient Profiles of Elderly People with Type 2 Diabetes and Chronic Kidney Disease Treated or Not with SGLT2 Inhibitors
by: Kyriaki Vafeidou, et al.
Published: (2025-05-01)

Effect of Sodium-Glucose Cotransporter Type 2 Inhibitors on The Development and Course of Atrial Fibrillation
by: D. A. Ishmaev, et al.
Published: (2025-01-01)

The Necrotic Mystery of Dapagliflozin
by: Rida Naqvi, et al.
Published: (2025-06-01)

Dapagliflozin’s Effects on Urinary Albumin and Non-Albumin Proteins in Diabetic and Non-Diabetic Kidney Transplant Recipients
by: Giancarlo Bilancio, et al.
Published: (2025-05-01)

Performance Enhancement of GPS/INS Integrated Navigation System Using Wavelet Based De-noising method
by: narjes davari, et al.
Published: (2016-11-01)

Flozins - modern treatment for patients with type 2 diabetes
by: Dominik Augustyn, et al.
Published: (2025-07-01)

Incidence of Glaucoma in Type 2 Diabetes Patients Treated With GLP‐1 Receptor Agonists: A Systematic Review and Meta‐Analysis
by: Maheen Asif, et al.
Published: (2025-07-01)

Effects of Empagliflozin on Sarcopenia Risk, Body Composition, and Muscle Strength in Type 2 Diabetes: A 24-Week Real-World Observational Study
by: Deniz Çetin, et al.
Published: (2025-06-01)

Sodium-glucose cotransporter 2 Inhibitors and COVID-19 outcomes in type 2 diabetes patients: A population-based cohort study
by: Cerina Dubois, et al.
Published: (2025-07-01)

The Clinically Significant Changes in the Composition and Functional Diversity of the Vaginal Microbiome in Women with Type 2 Diabetes Mellitus
by: Min Jeong Kim, et al.
Published: (2025-06-01)

Clinical use and monitoring of adverse effects of sodium‐glucose cotransporter‐2 inhibitors in persons with type 1 diabetes mellitus
by: Chinatsu Sakai, et al.
Published: (2025-08-01)

Role of sodium-glucose cotransporter 2 inhibitors in cardiovascular events in patients with heart failure
by: Eva Muja, et al.
Published: (2025-07-01)

Unveiling the anticancer potential of SGLT-2 inhibitors: mechanisms and prospects in clinical oncology—a narrative review
by: Jiaxin Li, et al.
Published: (2025-06-01)

Assessing the Efficacy and Safety of Dapagliflozin and Empagliflozin as an Add-on Therapy for Lowering Glycated Hemoglobin and Weight in Type 2 Diabetes Mellitus Patients
by: Mahima Makhija, Alka Bansal, Lokendra Sharma, Punam Jakhar, Susheel Kumar, Ashish Agrawal
Published: (2025-06-01)

Cardioprotective effects of dapagliflozin against the acute cardiotoxic effects of 5-fluorouracil
by: Mehmet Hakan Uzun, et al.
Published: (2025-07-01)

Impact of SGLT-2 Inhibitors on Biomarkers of Heart Failure
by: Dana Darwish, et al.
Published: (2025-06-01)

A Fault-Tolerant Localization Method for 5G/INS Based on Variational Bayesian Strong Tracking Fusion Filtering with Multilevel Fault Detection
by: Zhongliang Deng, et al.
Published: (2025-06-01)

Could Increased Glp1r Expression via Sitagliptin in the GLP-1/GLP-1 Receptor Axis in the DietInduced Obesity Rat Model be Important in Liver Metabolism?
by: Cem Horozoğlu, et al.
Published: (2024-12-01)

Efficacy of Empagliflozin in the Treatment of Experimental Myocardial Infarction
by: D. Yu. Ivkin, et al.
Published: (2023-12-01)

Secondary Erythrocytosis Among Type 2 Diabetes Mellitus Patients With Hypogonadism Using Sodium‐Glucose Cotransporter 2 Inhibitors and Testosterone Replacement Therapy
by: Maharan Kabha, et al.
Published: (2025-07-01)

SGLT2 inhibitors in autoimmune diseases: emerging therapeutic potential and clinical challenges
by: Taimin Luo, et al.
Published: (2025-07-01)

SGLT2 inhibitor therapy in overweight and obese patients with cystic fibrosis-related diabetes: Case series
by: Ammar Ahmed, et al.
Published: (2025-09-01)

TYPE 2 DIABETES AND CARDIOVASCULAR COMPLICATIONS: IS IT POSSIBLE TO IMPROVE PROGNOSIS BY GLUCOSE LOWERING THERAPY?
by: Zh. D. Kobalava, et al.
Published: (2018-09-01)

Efficacy and safety of empagliflozin in patients over 65 with type 2 diabetes mellitus complicating cardiorenal syndromes type II and IV
by: Cao Mugen, et al.
Published: (2025-01-01)